Related Experiment Videos
Controlling Neuropathic Pain in HIV
Susama Verma1, Lydia Estanislao, Letty Mintz
1Department of Neurology, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029, USA. david.simpson@mssm.edu
Current Infectious Disease Reports
|May 15, 2004
Summary
Painful HIV-associated neuropathy, especially distal symmetrical polyneuropathy (DSP), poses challenges. Treatment selection for this nerve pain involves balancing efficacy, safety, and cost, considering antiretroviral drug effects.
Area of Science:
- Neurology
- Infectious Diseases
- Pharmacology
Background:
- Neuropathic pain is a common complication of systemic illnesses like HIV infection.
- HIV-associated peripheral neuropathies, particularly distal symmetrical polyneuropathy (DSP), present significant diagnostic and therapeutic challenges.
- Neurotoxic antiretrovirals, especially dideoxynucleoside analogues, can cause or worsen DSP.
Purpose of the Study:
- To review current and emerging treatment options for painful HIV-associated neuropathy.
- To provide guidance on selecting pharmacologic interventions based on key criteria.
- To highlight experimental agents under investigation in clinical trials.
Main Methods:
- Literature review of neuropathic pain in HIV.
- Analysis of treatment strategies for distal symmetrical polyneuropathy (DSP).
- Evaluation of efficacy, safety, administration, and cost of pharmacologic interventions.
Main Results:
- Distal symmetrical polyneuropathy (DSP) is the most frequent HIV-associated neuropathy.
- Treatment decisions require careful consideration of drug-induced nerve damage.
- Various pharmacologic options, including experimental agents, are being studied.
Conclusions:
- Effective management of painful HIV neuropathy necessitates a comprehensive approach.
- Balancing treatment benefits against risks and costs is crucial for patient care.
- Ongoing research into novel therapeutic agents offers future treatment possibilities.